Tau PNU MEDICAL Co. Ltd.

Tau PNU MEDICAL Co. Ltd. specializes in innovative medical devices designed to treat tricuspid regurgitation, offering advanced solutions that enhance patient care without invasive surgical methods. Founded in 2014 and headquartered in Busan, South Korea, Tau PNU MEDICAL Co.

Ltd. operates in the medical technology sector focusing on devices for cardiac treatment. The company has raised a total of KRW 5000 million in Series A funding from K Bridge Ventures and Smilegate Investment as of September 15, 2017. CEO Peter Park leads the firm, which has made one significant deal thus far.

Tau Medical specializes in innovative medical devices aimed at addressing tricuspid regurgitation (TR) through their proprietary Pivot-TR platform. The core offerings include two distinct solutions: Pivot Extend®, a permanent implant designed for long-term valve support, and Pivot Bridge®, a temporary device that stabilizes frail or high-risk patients while facilitating their transition to future therapies. Both products utilize a minimally invasive transfemoral approach, negating the need for open-heart surgery and utilizing atraumatic anchoring that avoids tissue fixation. The target user base encompasses healthcare providers, particularly cardiologists and surgeons, who are tasked with treating patients suffering from TR, including those previously deemed too high-risk for such interventions.

The Pivot-TR solutions are designed for use in various global markets, including North America and Europe, where the demand for advanced cardiac therapies continues to grow. Tau Medical generates revenue primarily through the sale of its Pivot-TR products, engaging directly with healthcare institutions and medical practitioners who perform cardiac procedures. The transaction structure is based on a direct-to-consumer model in the B2B space, with hospitals and clinics purchasing the devices as needed for their patients. Given the specialized nature of the products, the revenue cycle includes one-time purchases of the implants, with potential for ongoing partnerships for training and support services related to the use of the devices.

While specific pricing structures for the products are not disclosed, it is anticipated that pricing reflects the advanced technology and clinical benefits provided by these innovative solutions. Looking ahead, Tau PNU MEDICAL Co. Ltd. plans to leverage its recent funding of KRW 5000 million from the Series A round to support the development of new products aimed at enhancing its Pivot-TR platform.

The company is actively designing innovative solutions and is eyeing expansion into new markets, particularly in North America and Europe, by 2025. The recent funding will also be utilized to enhance their marketing efforts and establish partnerships with healthcare providers across these regions.